IDEAYA Q2 net loss $77.5M; cash ~$992M; darovasertib PFS data on track for YE2025

IDEAYA Biosciences, Inc.

2025-Q2 EPS reported -$1.69

Net loss of $77.5M for Q2 2025 vs $72.2M in Q1 2025; R&D expenses $74.2M, G&A $14.6M.
Cash, cash equivalents and marketable securities ~$992M as of June 30, 2025, down from $1.05B at March 31, 2025.
Darovasertib/crizotinib Phase 2/3 trial in 1L HLA-A2-negative MUM enrolled over 350 patients; median PFS data on track for YE2025 to potentially enable accelerated approval filing.
Three IND submissions by YE2025: IDE892 (PRMT5), IDE034 (B7H3/PTK7 bispecific ADC), IDE574 (KAT6/7).
IDEAYA to host R&D Day on Sept 8, 2025, with multiple clinical data updates including neoadjuvant darovasertib and IDE397 combo data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.